Cat No.
CEI-0111
Description
As a dual inhibitor of mTOR/PI3k, XL765 shows inhibition to mTOR, p110alpha, p110beta, p110gamma and p110delta with IC50 of 157 nM, 39 nM, 113 nM, 9 nM and 43 nM.
Alias
SAR245409
Synonyms
SAR245409
CAS No.
1349796-36-6
Targets
MTOR, p110alpha, p110beta, p110gamma, p110delta
Chemical Name
Benzamide, N-[4-[[[3-[(3,5-dimethoxyphenyl)amino]-2-quinoxalinyl]amino]sulfonyl]phenyl]-3-methoxy-4-methyl-
M.Wt
599.66
Purity
>99%
Solubility
DSMO 15 mg/mL Water
Storage
2 years at -20 centigrade
In vitro
As a dual inhibitor of mTOR/PI3k, XL765 shows inhibition to mTOR, p110alpha, p110beta, p110gamma and p110delta with IC50 of 157 nM, 39 nM, 113 nM, 9 nM and 43 nM. XL765 treatment results in decreased cell viability in 13 PDA cell lines in a dose-dependent manner. XL765, a dual-target PI3K/mTOR inhibitor, inhibits cell growth and apoptosis in many more cell lines and at lower concentrations as compared to the PI3K-selective inhibitors XL147 and PIK90.
In vivo
The combination of XL765 (30 mg/kg) with chloroquine (50 mg/kg) results in significant inhibition of BxPC-3 xenograft growth in mice models, while XL765 alone at the same dose has no inhibitory effect.
